Trabectedin As Second Line And Beyond In Advanced Leiomyosarcoma

e21522 Background: Trabectedin is approved in the European Union for patients (pts) with advanced soft tissue sarcoma (STS) after failure of anthracyclines or ifosfamide. Methods: Consecutive pts with advanced/metastatic leiomyosarcoma receiving trabectedin (1.5 mg/m2 every 3 weeks, up to 6 cycles) in our institution were included in this retrospective review. Results: Between March 1999 and January 2013, thirty six pts (16 males, median age: 54 years, range: 31-78) were started with trabectedin 1.5 mg/m2 (15% had subsequent dose reduction for grade 3/4 toxicity). Tumor grades were G1 (n=3), G2 (n=16), G3 (n=17).Primary tumor sites included extremities (n=7), abdomen/retroperitoneum (n=16), vascular (n=8) and other (n=5). Pts had received one (n=19), two (n = 13) or more (n=4) previous lines of chemotherapy. Metastatic sites were: lung (n=30), liver (n=21), bone (n=8). 24 pts had ≥2 metastatic sites. A total of 241 cycles were administered (median: 6 cycles/pt, range 1-26). Best response according to RECI...